REQUEST A DEMO
Total
USD $0.00
Search more companies

Icure Pharmaceutical Incorporation (South Korea)

Main Activities: Pharmaceutical and Medicine Manufacturing | Medicinal and Botanical Manufacturing
Full name: Icure Pharmaceutical Incorporation Profile Updated: July 27, 2024
Buy our report for this company USD 29.95 Most recent financial data: 2023 Available in: English Download a sample report

The Company is a Korea-based company mainly engaged in the production and sale of cosmetics. Along with subsidiaries, the Company operates its business through two segments. The Cosmetic segment is involved in the manufacturing and sale of cosmetics including basic cosmetics, mask packs, and patches. In addition, it is also engaged in the production and sale of body, hair care products and fragrances. The cosmetics are sold under the names of Botalinum, Mediheal N.M.F, Meditime, among others. The Pharmaceutical segment is engaged in the manufacturing and sale of over the counter (OTC) drugs, ethical the counter (ETC) drugs, as well as quasi drugs. The OTC drugs include anti-inflammatory analgesics and dementia treatments. The Company distributes its products within the domestic market and to overseas markets. The Company was established on May 29, 2000. The Company share was listed on the Korea Securities Dealers Automated Quotation System ( KOSDAQ ) on July 12, 2018.

Headquarters
10, Bongeunsa-Ro 104-Gil, Gangnam-Gu
Seoul; Seoul;

Contact Details: Purchase the Icure Pharmaceutical Incorporation report to view the information.

Website: http://icure.co.kr

Basic Information
Total Employees:
Purchase the Icure Pharmaceutical Incorporation report to view the information.
Outstanding Shares:
Purchase the Icure Pharmaceutical Incorporation report to view the information.
Registered Capital:
Purchase the Icure Pharmaceutical Incorporation report to view the information.
Financial Auditors:
Purchase the Icure Pharmaceutical Incorporation report to view the information.
Incorporation Date:
May 29, 2000
Key Executives
Purchase this report to view the information.
Chief Executive Officer
Purchase this report to view the information.
Outside Director
Purchase this report to view the information.
Auditor
Purchase this report to view the information.
Auditor
Purchase this report to view the information.
Auditor
Ownership Details
Purchase this report to view the information.
19.9%
Purchase this report to view the information.
1.1%
Purchase this report to view the information.
0.9%
Subsidiaries
(주)아이큐어비앤피
100%
아이콰(상해)국제유한공사
100%
(주)오티케이씨앤티
90%
Company Performance
Financial values in the chart are available after Icure Pharmaceutical Incorporation report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency KRW. Absolute financial data is included in the purchased report.
Net sales revenue
1.93%
Total operating revenue
-3.34%
Operating profit (EBIT)
41.38%
EBITDA
-8.61%
Net Profit (Loss) for the Period
34.16%
Total assets
-13.14%
Total equity
-35.17%
Operating Profit Margin (ROS)
19.02%
Net Profit Margin
16.82%
Return on Equity (ROE)
-0.14%
Debt to Equity Ratio
58.21%
Quick Ratio
-0.28%
Cash Ratio
-0.09%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?